Biocryst Pharmaceuticals
Clinical trials sponsored by Biocryst Pharmaceuticals, explained in plain language.
-
Lifeline for HAE patients: study offers continued access to promising drug
Disease control ENROLLING_BY_INVITATIONThis study provides ongoing access to berotralstat for up to 139 people with hereditary angioedema (HAE) who previously took part in berotralstat trials. The main goal is to monitor safety and side effects over time. Participants take the medication daily to help control their co…
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:39 UTC
-
New hope for kids with rare swelling disorder: daily pill may prevent attacks
Disease control OngoingThis study tests a daily medication called berotralstat in children aged 2 to under 12 who have hereditary angioedema (HAE), a rare condition that causes sudden, painful swelling attacks. The goal is to find the right dose based on the child's weight and to check if the drug is s…
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
New eye injection shows early promise for diabetes-related vision loss
Disease control OngoingThis early-phase study tests a single injection of avoralstat into the eye for people with diabetic macular edema, a condition that causes vision loss. Nine adults with diabetes and center-involved swelling in the retina will be monitored for safety and any signs of improvement i…
Phase: PHASE1 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:38 UTC